Hirano Kenichi

2020 - 2021 -

2019 - 2020 オミックス解析に基づく心不全発症・重症化予測マーカーの開発と心不全発症・重症化機序の解明

2018 - 2019 Development of capsules containing highly purified tricaprin (CNT-01) for triglyceride deposit cardiomyovasculopathy

2017 - 2018 中性脂肪蓄積心筋血管症(TGCV)に対する末梢血を使った診断機器の開発

2015 - 2018 中性脂肪蓄積心筋血管症に対する中鎖脂肪酸を含有する医薬品の開発

2016 - 2017 中性脂肪蓄積心筋血管症(TGCV)に対する末梢血を使った診断機器の開発

2012 - 2015 -

2012 - 2014 -

2011 - 2013 Development of dietary therapy for triglyceride deposit cardiomyovasculopathy

2011 - 2012 -

2010 - 2012 -

2010 - 2012 -

2010 - 2011 -

2010 - 2011 -

2009 - 2010 -

2009 - 2010 -

2009 - 2010 -

2004 - 2005 Molecular mechanism for the phenotypic expression of metabolic syndrome. -CD36 deficiency as a model-

2002 - 2003 Molecular Mechanism for Intracellular Signaling through CD36

2001 - 2002 CD36 AS A GENETIC BACKGROUND FOR METABOLIC SYNDROME AND ATHEROSCLEROTIC CARDIOVASCULAR DISEASE

2001 - 2002 DEVELOPMENT OF ELISA METHOD FOR THE MEASUREMENT OF APOLIPOPROTEIN B48

2000 - 2001 Establishment of A New Strategy for the Treatment of Atherosclerosis by Activating Reverse Cholesterol Transport

2000 - 2001 Development of Oxidized LDL Receptor (CD36) Knockout Mice and Its Application to Elucidation of Molecular Mechanism for Atherogenesis

1999 - 2000 Establishment of A New Strategy for the Treatment of Atherosclerosis by Activating Reverse Cholesterol Transport

1998 - 1999 Generation of the lecithin : cholesterol acyltransferase (LCAT) knockout mouse and the investigation of the relation between LCAT and atherosclerosis.

1998 - -

1994 - 1995 Molecular Biological Study on the Role of Heparic Lipase on Arherogenesis

1992 - 1993 Cell-biological and molecular biological analyzes of reverse cholesterol transport as a protective system against atherosclerosis

新規動脈硬化治療法の開発

インスリン抵抗性の分子機構

動脈硬化の発症、進展、防御の分子機構の解明

Novel treatment for atherosclerotic cardiorascular disease